Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate

References

• Kim JJ, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol. 2012 Jul 25;358(2):223–231.
   PubMed Web of Science ®Google Scholar
• Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016. Jul 27. [Epub ahead of print].
   PubMedGoogle Scholar
• Biglia N, Carinelli S, Maiorana A, et al. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Devel Ther. 2014;20(8):285–292.
   Google Scholar
• Chabbert-Buffet N, Meduri G, Bouchard P, et al. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005;11:293–307.
   PubMed Web of Science ®Google Scholar
• Nieman LK, Blocker W, Nansel T, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril. 2011 Feb;95(2):767–772.
   Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P, et al. Loumaye E; PEARL I study group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012 Feb;2(366):409–420.
   Google Scholar
• Donnez J, Tomaszewski J, Vázquez F, et al. Loumaye E; PEARL II study group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012 Feb;2(366):421–432.
   Google Scholar
• Donnez J, Vázquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014 Jun;101:1565–1573.
   PubMed Web of Science ®Google Scholar
• Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103:519–527.
   PubMed Web of Science ®Google Scholar
• Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016;105:165–173.
   PubMed Web of Science ®Google Scholar
• Donnez J, Arriagada P, Donnez O, et al. Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators. Curr Opin Obstet Gynecol. 2015;27:422–431.
   PubMed Web of Science ®Google Scholar
• Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril. 2011;96:1175–1189.
   PubMed Web of Science ®Google Scholar
• Courtoy GE, Donnez J, Marbaix E, et al. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril. 2015 Aug;104:426–434.
   PubMed Web of Science ®Google Scholar
• Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21:591–598.
   PubMed Web of Science ®Google Scholar
• Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update. 2007;13:567–580.
   PubMed Web of Science ®Google Scholar
• Williams AR, Critchley HO, Osei J, et al. The effects of the selective progesterone receptor modulator asoprisnil on themorphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod. 2007;22:1696–1704.
   PubMed Web of Science ®Google Scholar
• Williams AR, Bergeron C, Barlow DH, et al. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol. 2012;31:556–569.
   PubMed Web of Science ®Google Scholar
• Fauser B, Donnez J, Bouchard P, et al. 2016. Safety after extended repeated use of ulipristal acetate for uterine fibroids. Obst Gynecol. Submitted.
   Google Scholar
• Chantraine F, Poismans G, Nwachuku J, et al. Expulsion of a uterine myoma in a patient treated with ulipristal acetate. Clin Case Rep. 2015;3:240–242.
   PubMed Web of Science ®Google Scholar
• Willame A, Marci R, Petignat P, et al. Myoma migration: an unexpected “effect” with ulipristal acetate treatment. Eur Rev Med Pharmacol Sci. 2016;20:1439–1444.
   PubMed Web of Science ®Google Scholar
• Farquhar CM, Lethaby A, Sowter M, et al. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am J Obstet Gynecol. 1999;181:525–529.
   PubMed Web of Science ®Google Scholar
• Anastasiadis PG, Skaphida PG, Koutlaki NG, et al. Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding. Eur J Gynaecol Oncol. 2000;21:131–134.
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard PVA2914 Study Group.Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trialJ Clin Endocrinol Metab. 2007Sep923582–3589
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Pintiaux A, Bouchard P. The immninent dawn of SPRMs in obstetrics and gynecology. Mol Cel Endocrinol. 2012;02:21.
   Google Scholar
• Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception. 2010 Nov;82:442–452.
   PubMed Web of Science ®Google Scholar
• Munro MG, Critchley HO, Broder MS, et al. FIGO classification system (PALM- COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. FIGO working group on menstrual disorders. Int J Gynaecol Obstet. 2011;113:1–2.
   PubMed Web of Science ®Google Scholar
• Huang Y, Jensen JT, Brache V, et al. A randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: research for a novel estrogen-free method of contraception. Contraception. 2014;90:565–574.
   PubMed Web of Science ®Google Scholar